• Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR US) 2020

  • Collaborator: Ipsen

  • Authors: A. Esquenazi, J. Jorge, P. Varriale, E. Pain, A. Lysandropoulos

Botulinum toxin-A (BoNT-A) injections are first-line treatment for adult spasticity. Prior patient surveys have reported that BoNT-A treatment improves quality of life but that symptoms usually recur before the next injection.

Objective:  Present the self-reported impact of spasticity and waning of effect of Botulinum Toxin A (BoNT-A) treatment on patients’ quality of life (QoL) and employment status.